13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001400240
Total reported value
$1.5B
$1.5B
5 檔
75.4%
As reported in its official Q1 2026 Form 13F filing, Flagship Pioneering, LLC's tracked investment portfolio stood at $1.5B with 5 total positions.
In Q1 2026, Flagship Pioneering, LLC displayed an active expansion posture, initiating 1 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GENB | Generate Biomedicines Inc | Stock-Other | 67.44% | +1.22% | — | |
| 2 | MRNA | Moderna Inc | Stock-Healthcare | 20.26% | +0.81% | — | |
| 3 | SANA | Sana Biotechnology Inc | Stock-Other | 6.20% | -0.53% | — | |
| 4 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 5.22% | -1.20% | — | |
| 5 | MCRB | Seres Therapeutics Inc | Stock-Other | 0.88% | -0.29% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MCRB | Seres Therapeutics Inc | -4.4% | — | Unchanged |
| 2 | FHTX | Foghorn Therapeutics Inc | -15.9% | — | Unchanged |
| 3 | MRNA | Moderna Inc | -21.9% | — | Unchanged |
| 4 | SANA | Sana Biotechnology Inc | -25.2% | — | Unchanged |
| 5 | GENB | Generate Biomedicines Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Flagship Pioneering, LLC reported a total U.S. public equity portfolio value of $1.5B across 5 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GENB, MRNA, SANA) accounted for 75.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
GENB
市值: $783.4M
During Q1 2026, Flagship Pioneering, LLC's top holdings by market value included GENB (67.4%)、MRNA (20.3%)、SANA (6.2%). The largest single position, GENB, represented 67.4% of total portfolio value.
In Q1 2026, Flagship Pioneering, LLC made 1 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.